Azithropine

FDA Approves Azathioprine Generic Drug Product

WESTPORT, Jul 29 (Reuters Health) -

Applied Analytical Industries, Inc. (AAI), based in Wilmington, North
Carolina, announced on Wednesday that it and Geneva Pharmaceuticals,
Inc. have received approval from the US Food and Drug Administration to
market azathioprine tablets, a generic formulation of Glaxo Wellcome's
immunosuppressive agent Imuran.

Under an agreement between the two companies, AAI will manufacture the
tablets and Geneva will handle marketing and distribution.

"The market for azathioprine in 1998 was $50 million," Alan Lernier,
director of licensing and business development for AAI, noted.
"Competition is limited due to the difficulty of manufacturing the
product. Azathioprine represents a profitable addition to AAI's licensed
product portfolio."

Copyright 1999 Reuters Limited. All rights reserved.

DISCLAIMER:

The materials and information on this server are intended for educational and informational purposes only. The materials and information are not intended to replace the services of a trained health professional or to be a substitute for medical advice of physicians and/or other health care professionals. The International Still's Disease Foundation is not engaged in rendering medical or professional medical services. You should consult your physician on specific medical questions, particularly in matters requiring diagnosis or medical attention. The International Still's Disease Foundation makes no representations or warranties with respect to any treatment, action, application medication or preparation by any person following the information offered or provided within this website. Any information used from other websites was done so with permission from each site, with an exception to those of "public domain", whereas we believe any site without a cited reference was a "public domain site" and for our use. The International Still's Disease Foundation is a non-profit organization. This page was last updated on June 13, 2002